BR100 Decreased By (-0.83%)
BR30 Decreased By (-1.36%)
KSE100 Decreased By (-0.81%)
KSE30 Decreased By (-0.79%)
BECO 5.53 Decreased By ▼ -0.10 (-1.78%)
BML 57.95 Decreased By ▼ -1.57 (-2.64%)
BOP 35.20 Decreased By ▼ -0.85 (-2.36%)
CNERGY 8.22 Decreased By ▼ -0.22 (-2.61%)
DCL 11.64 Decreased By ▼ -0.28 (-2.35%)
FCCL 56.90 Decreased By ▼ -1.17 (-2.01%)
FCSC 5.39 Decreased By ▼ -0.14 (-2.53%)
FFL 18.13 Decreased By ▼ -0.24 (-1.31%)
FNEL 1.31 Decreased By ▼ -0.01 (-0.76%)
HUMNL 11.18 Decreased By ▼ -0.32 (-2.78%)
KEL 8.15 Decreased By ▼ -0.29 (-3.44%)
KOSM 6.96 Decreased By ▼ -0.02 (-0.29%)
MLCF 100.52 Decreased By ▼ -1.95 (-1.9%)
NBP 203.51 Decreased By ▼ -3.96 (-1.91%)
PACE 11.21 Decreased By ▼ -0.36 (-3.11%)
PAEL 42.75 Decreased By ▼ -0.98 (-2.24%)
PIAHCLA 26.31 Decreased By ▼ -0.76 (-2.81%)
PIBTL 17.94 Decreased By ▼ -0.28 (-1.54%)
PPL 241.94 Decreased By ▼ -7.12 (-2.86%)
PRL 35.97 Decreased By ▼ -0.67 (-1.83%)
PTC 65.58 Decreased By ▼ -1.44 (-2.15%)
SEARL 94.40 Decreased By ▼ -1.52 (-1.58%)
SSGC 31.32 Increased By ▲ 0.69 (2.25%)
TELE 9.07 Decreased By ▼ -0.25 (-2.68%)
THCCL 67.62 Decreased By ▼ -1.63 (-2.35%)
TPLP 10.24 Decreased By ▼ -0.80 (-7.25%)
TREET 25.84 Decreased By ▼ -0.76 (-2.86%)
TRG 66.68 Decreased By ▼ -3.16 (-4.52%)
WAVES 11.05 Decreased By ▼ -0.22 (-1.95%)
WTL 1.29 Decreased By ▼ -0.02 (-1.53%)
Business & Finance

Johnson & Johnson announces new CEO

  • Gorsky, the CEO since 2012, is stepping aside "due to family health reasons," according to a company press release, which said he will stay on as executive chairman
Published August 20, 2021 Updated August 20, 2021 09:50am
By

NEW YORK: Alex Gorsky will step down as chief executive of Johnson & Johnson in January, ceding the role to longtime company executive Joaquin Duato, the health care giant announced Thursday.

Gorsky, the CEO since 2012, is stepping aside "due to family health reasons," according to a company press release, which said he will stay on as executive chairman.

Gorsky oversaw development of the company's one-shot Covid-19 vaccine. His tenure also coincided with a 60 percent increase in research and development, the company said.

Pharmaceutical firms rake in billions with Covid jabs

He has also been at the helm during a recent settlement with US states over opioids, agreeing to pay up to $5 billion over nine years.

However, the company still faces litigation from plaintiffs who have sued J&J, alleging talcum products caused cancer.

Duato, currently the vice chairman of the company's executive committee, will also join the company's board of directors.

"I am honored to serve as Johnson & Johnson's next CEO," Duato said in the press release.

"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson's opportunity to play a key role in meaningfully improving the global trajectory of human health."

Comments

Comments are closed for this article.